DARZALEX
DARZALEX- daratumumab injection, solution, concentrate
DARZALEX IV- daratumumab injection, solution, concentrate
Janssen Biotech, Inc.
1 INDICATIONS AND USAGE
DARZALEX is indicated for the treatment of adult patients with multiple myeloma:
- in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy.
- in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant.
- in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant.
- in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy.
- in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.
- in combination with pomalidomide and dexamethasone in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
- as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.
2 DOSAGE AND ADMINISTRATION
2.1 Important Dosing Information
- Administer pre-infusion and post-infusion medications [see Dosage and Administration (2.3)] .
- Administer only as an intravenous infusion after dilution in 0.9% Sodium Chloride Injection, USP [see Dosage and Administration (2.5)].
- DARZALEX should be administered by a healthcare provider, with immediate access to emergency equipment and appropriate medical support to manage infusion-related reactions if they occur [see Warnings and Precautions (5.1)].
- Type and screen patients prior to starting DARZALEX [see Warnings and Precautions (5.2)] .
2.2 Recommended Dosage
Monotherapy and In Combination with Lenalidomide (D-Rd) or Pomalidomide (D-Pd) and Dexamethasone
The DARZALEX dosing schedule in Table 1 is for combination therapy (4-week cycle regimens) and monotherapy as follows:
- combination therapy with lenalidomide and low-dose dexamethasone for newly diagnosed patients ineligible for autologous stem cell transplant (ASCT) and in patients with relapsed/refractory multiple myeloma
- combination therapy with pomalidomide and low-dose dexamethasone for patients with relapsed/refractory multiple myeloma
- monotherapy for patients with relapsed/refractory multiple myeloma.
The recommended dose of DARZALEX is 16 mg/kg actual body weight administered as an intravenous infusion according to the following dosing schedule:
Weeks | Schedule |
---|---|
Weeks 1 to 8 | weekly (total of 8 doses) |
Weeks 9 to 24 * | every two weeks (total of 8 doses) |
Week 25 onwards until disease progression † | every four weeks |
For dosing instructions of combination agents administered with DARZALEX, see Clinical Studies (14) and manufacturer’s prescribing information.
In Combination with Bortezomib, Melphalan and Prednisone (D-VMP)
The DARZALEX dosing schedule in Table 2 is for combination therapy with bortezomib, melphalan and prednisone (6-week cycle regimen) for patients with newly diagnosed multiple myeloma ineligible for ASCT.
The recommended dose of DARZALEX is 16 mg/kg actual body weight administered as an intravenous infusion according to the following dosing schedule:
Weeks | Schedule |
---|---|
Weeks 1 to 6 | weekly (total of 6 doses) |
Weeks 7 to 54 * | every three weeks (total of 16 doses) |
Week 55 onwards until disease progression † | every four weeks |
For dosing instructions of combination agents administered with DARZALEX see Clinical Studies (14.1).
In Combination with Bortezomib, Thalidomide and Dexamethasone (D-VTd)
The DARZALEX dosing schedule in Table 3 is for combination therapy with bortezomib, thalidomide, and dexamethasone (4-week cycle regimen) for patients with newly diagnosed multiple myeloma eligible for ASCT.
The recommended dose of DARZALEX is 16 mg/kg actual body weight administered as an intravenous infusion according to the following dosing schedule:
Treatment phase | Weeks | Schedule |
---|---|---|
Induction | Weeks 1 to 8 | weekly (total of 8 doses) |
Weeks 9 to 16 * | every two weeks (total of 4 doses) | |
Stop for high dose chemotherapy and ASCT | ||
Consolidation | Weeks 1 to 8 † | every two weeks (total of 4 doses) |
For dosing instructions of combination agents administered with DARZALEX, see Clinical Studies (14.1) and the manufacturer’s prescribing information.
In Combination with Bortezomib and Dexamethasone (D-Vd)
The DARZALEX dosing schedule in Table 4 is for combination therapy with bortezomib and dexamethasone (3-week cycle) for patients with relapsed/refractory multiple myeloma.
The recommended dose of DARZALEX is 16 mg/kg actual body weight administered as an intravenous infusion according to the following dosing schedule:
Weeks | Schedule |
---|---|
Weeks 1 to 9 | weekly (total of 9 doses) |
Weeks 10 to 24 * | every three weeks (total of 5 doses) |
Week 25 onwards until disease progression † | every four weeks |
For dosing instructions of combination agents administered with DARZALEX see Clinical Studies (14.2) and manufacturer’s prescribing information .
In Combination with Carfilzomib and Dexamethasone (DKd)
The recommended dosage for DARZALEX when administered in combination with carfilzomib and dexamethasone (4-week cycle) for patients with relapsed/refractory multiple myeloma is provided in Table 5.
Weeks | DARZALEX Dose * | Schedule |
---|---|---|
Week 1 | 8 mg/kg | days 1 and 2 (total 2 doses) |
Weeks 2 to 8 | 16 mg/kg | weekly (total of 7 doses) |
Weeks 9 to 24 † | 16 mg/kg | every two weeks (total of 8 doses) |
Week 25 onwards until disease progression ‡ | 16 mg/kg | every four weeks |
For dosing instructions of combination agents administered with DARZALEX see Clinical Studies (14.1) and manufacturer’s prescribing information .
Infusion Rates
Administer DARZALEX intravenously at the infusion rate described below in Table 6. Consider incremental escalation of the infusion rate only in the absence of infusion-related reactions.
The recommended dose of 16 mg/kg to be administered on Day 1 when DARZALEX is administered as monotherapy or in combination may be split over two consecutive days, such that an 8 mg/kg dose is administered on Day 1 and Day 2, respectively.
Dilution volume | Initial rate (first hour) | Rate increment * | Maximum rate | |
---|---|---|---|---|
| ||||
Week 1 Infusion | ||||
Option 1 (Single dose infusion) | ||||
Week 1 Day 1 (16 mg/kg) | 1,000 mL | 50 mL/hour | 50 mL/hour every hour | 200 mL/hour |
Option 2 (Split dose infusion) | ||||
Week 1 Day 1 (8 mg/kg) | 500 mL | 50 mL/hour | 50 mL/hour every hour | 200 mL/hour |
Week 1 Day 2 (8 mg/kg) | 500 mL | 50 mL/hour | 50 mL/hour every hour | 200 mL/hour |
Week 2 (16 mg/kg) † | 500 mL | 50 mL/hour | 50 mL/hour every hour | 200 mL/hour |
Week 3 onwards (16 mg/kg) ‡ | 500 mL | 100 mL/hour | 50 mL/hour every hour | 200 mL/hour |
Missed DARZALEX Doses
If a dose of DARZALEX is missed, administer the dose as soon as possible and adjust the dosing schedule to maintain the dosing interval.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.